Pfizer Inc.'s new experimental heart drug is dead, but the dual approach the company was testing -- boosting good cholesterol while lowering the bad -- is very much alive, specialists said Monday.A drug already on the market, Niaspan, raises good cholesterol without serious risks, and a large federal study is testing it with statin medications -- the very thing Pfizer was trying to do before being forced to abandon research on its drug, torcetrapib, over the weekend because of safety problems.
For consumers, the main fallout may be a delay in getting a new medicine that avoids Niaspan's chief side effect, a hot prickly sensation called flushing that patients hate but that can be minimized, doctors said.
Pfizer Inc. said Saturday it has cut off all clinical trials and development for a cholesterol drug that was supposed to be the star of its pipeline because of an unexpected number of deaths and cardiovascular problems in patients who used it.
Two pharmaceutical drug distributors pleaded guilty Thursday to taking part in a $42 million conspiracy to illegally import and sell the cholesterol reduction drug Lipitor and other medicines.